AbbVie wows with $30bn blockbuster

Gonzalez, Richard (Abbvie) Richard Gonzalez from PA 15Nov19 230x150
By David Rothnie
14 Nov 2019

AbbVie enjoyed the undivided attention of US bond investors on Tuesday when it hit the market with a $30bn 10 tranche deal that, remarkably for such a big deal, priced with a negative new issue concession.

Proceeds will be used to help finance AbbVie’s $63bn acquisition of botox maker Allergan, which was given regulatory approval on October 25. (Picture shows AbbVie's CEO Richard Gonzalez)

Investors poured $75bn of orders into the biggest high grade deal of the year, underlining the amount of money they ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.